Cargando…

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

BACKGROUND: The antitumor effect of a drug is considered to be associated with a decrease in tumor blood flow. AIMS: We investigated whether the efficacy of lenvatinib (LEN) could be accurately assessed by measuring blood flow in hepatocellular carcinoma (HCC) during early treatment stages. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamachi, Naoki, Nakano, Masahito, Okamura, Shusuke, Niizeki, Takashi, Iwamoto, Hideki, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Kuromatsu, Ryoko, Koga, Hironori, Torimura, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842703/ https://www.ncbi.nlm.nih.gov/pubmed/34105904 http://dx.doi.org/10.1002/cnr2.1471

Ejemplares similares

Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma
por: Okamura, Shusuke, et al.
Publicado: (2022)

Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020)

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion
por: Niizeki, Takashi, et al.
Publicado: (2021)

Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study
por: Shirono, Tomotake, et al.
Publicado: (2021)

Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma
por: Shirono, Tomotake, et al.
Publicado: (2022)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
por: Iwamoto, Hideki, et al.
Publicado: (2020)

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
por: Shimose, Shigeo, et al.
Publicado: (2023)

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis
por: Shirono, Tomotake, et al.
Publicado: (2021)

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
por: Zaizen, Yuki, et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2022)

Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma
por: Nakano, M., et al.
Publicado: (2021)

Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2022)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
por: Shimose, Shigeo, et al.
Publicado: (2020)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Shimose, Shigeo, et al.
Publicado: (2023)

Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
por: Suzuki, Hiroyuki, et al.
Publicado: (2023)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2022)

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
por: Iwamoto, Hideki, et al.
Publicado: (2023)

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2021)

Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces “angiogenic switch off” in a hepatoma mouse model
por: Iwamoto, Hideki, et al.
Publicado: (2015)

The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
por: Koga, Hironori, et al.
Publicado: (2023)

Total and High Molecular Weight Adiponectin and Hepatocellular Carcinoma with HCV Infection
por: Sumie, Shuji, et al.
Publicado: (2011)

Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)
por: Nakano, Dan, et al.
Publicado: (2020)

Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Surgically treated diaphragmatic perforation after radiofrequency ablation for hepatocellular carcinoma
por: Nagasu, Sachiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i1mn4dksbuq12g80hkcbkhtgu5